iLCT Pipeline project: Theracurmin
This preclinical study aims to assess whether Theracurmin – a formulation of curcumin – can slow progression in models of Parkinson’s. Contents About the study Curcumin, a compound found in turmeric, is well known for its antioxidant and anti-inflammatory properties; because of this, researchers have...
Rifabutin for Parkinson’s
This preclinical study is assessing whether rifabutin, an antibiotic, can protect nerve cells (neurons) by reducing levels of alpha-synuclein. Contents About the study Dr Lorraine Kalia at University Health Network, Toronto is investigating the antibiotic rifabutin as a potentially disease-modifying drug in laboratory models of...
AAV-hGDF5 for Parkinson’s
This study is evaluating whether the neurotrophic factor GDF5 can slow the progression in models of Parkinson’s. Contents About the study Growth differentiation factor 5 (GDF5) is a neurotrophic factor – proteins that promote the growth, development, and survival of neurons. GDF5 belongs to the...
iLCT Pipeline Project: Carnosic acid
This preclinical project aims to determine whether carnosic acid – a compound found in rosemary and sage – can slow progression in models of Parkinson’s. Contents About the study In this study, Dr Sinead A. O’Sullivan and Prof. Donato A. Di Monte at the German...
Screening iLCT-evaluated drugs
This preclinical study will compare the effectiveness of 100 drugs previously evaluated by our iLCT committee to better prioritise the most promising compounds for clinical trial. Contents About the study Prof Heather Mortiboys at the University of Sheffield will be conducting a two-year pre-clinical study...
iLCT Pipeline Project: Probucol and chlorogenic acid
This preclinical study aims to gather evidence on whether two compounds – probucol and chlorogenic acid – have a neuroprotective effect in models of Parkinson’s. Contents About the study Both probucol and chlorogenic acid have been evaluated by the International Linked Clinical Trials (iLCT) committee,...
MANF and CDNF mimics
This preclinical study aims to assess if small-molecule mimics of the nerve growth factors MANF and CDNF are neuroprotective and able to slow Parkinson’s progression. Contents About the study Nerve growth factors, or neurotrophic factors, are proteins that support the growth and development of nerve...
CP-6: a nitroalkene for Parkinson’s
This preclinical study aims to assess if the novel drug CP-6 is neuroprotective in models of Parkinson’s. Contents About the study Developed by Creegh Pharmaceuticals, CP-6 is a new synthetic, or man-made, version of a type of fatty acid called a nitroalkene. Fatty acids are...
Repurposing anti-gout medication for Parkinson’s
The goal of this preclinical study was to determine whether two anti-gout medications could slow progression in models of Parkinson’s. Contents About the study Professor Heather Mortiboys at the University of Sheffield conducted an 18-month preclinical study on two anti-gout medications – probenecid and thiosalicylic...
GAin-PD
In this preclinical study, researchers are interested in whether bacterial-derived anti-inflammatory molecules can lower the risk of Parkinson’s onset and slow progression. Contents About the study Dr. Sandra Morais Cardoso from the University of Coimbra in Portugal is evaluating whether treatment of gut inflammation via...